Objectives: To investigate an outbreak of linezolid-resistant Staphylococcus epidermidis (LRSE) in an interdisciplinary ICU, linezolid consumption and infection control measures taken.
Introduction
Oxazolidinones represent a class of synthetic bacterial agents with activity against Gram-positive organisms. Linezolid was the first oxazolidinone introduced for clinical use. Indications comprise the treatment of uncomplicated and complicated skin and skin structure infections and hospital-and community-acquired pneumonia. It is also used as a last-resort antibiotic to treat infections with MDR bacteria including some Staphylococcus species. 1 Oxazolidinones disrupt bacterial protein synthesis by binding to the peptidyl transferase centre of the ribosome, thereby inhibiting transition of aminoacyl-tRNA to the A site. 2 Development of linezolid resistance among staphylococci is based on multiple mechanisms: (i) mutations in the linezolid 23S rRNA binding site; (ii) mutations in genes encoding the 50S ribosomal proteins L3, L4 and L22 of the peptide translocation centre (PTC) of the ribosome; and (iii) acquisition of a plasmid-encoded, transferable methyltransferase cfr and/or the ABC transporter optrA.
3 While optrA confers non-susceptibility to oxazolidinones and phenicols, the methyltransferase cfr mediates resistance to at least five antimicrobial classes, resulting in a phenotype referred to as PhLOPSA (phenicols, lincosamides, oxazolidinones, pleuromutilins and streptogramin A antibiotics). [4] [5] [6] [7] [8] Among CoNS, Staphylococcus epidermidis causes the greatest number of infections. S. epidermidis are commensal bacteria; therefore, infections in humans with these opportunistic bacteria are often linked to implanted medical devices or to immunesuppression therapy. 9, 10 Especially implant-associated infections are difficult to treat due to the fact that clinical S. epidermidis isolates very often exhibit an MDR phenotype. 11 isolates are rare. 1, 12, 13 However, outbreaks with linezolidresistant S. epidermidis (LRSE) have been recently reported from countries worldwide. 11, [14] [15] [16] [17] [18] Some reports could link the prolonged or increased linezolid utilization to the emergence of linezolid-resistant strains. 10, 17, 19 Linezolid-dependent growth of S. epidermidis strains, as shown for ST22 clones from Greece, was speculated to be causative for this observation. 18, 20 Here, we report the molecular epidemiology, control and management of LRSE in an interdisciplinary ICU of a secondary care hospital in North Rhine-Westphalia, Germany. The detection of the cfr gene in highly similar extrachromosomal DNA in different genetic backgrounds of LRSE suggested transmissibility of the resistance gene cfr.
Methods

Ethics approval
All patient data used in this scientific work were anonymized. According to the German Protection against Infection Act [Infektionsschutzgesetz (IfSG)], infection control units are obliged not only to investigate possible nosocomial outbreaks but also to intervene with adequate infection control measures deduced from results of outbreak investigations. 21 Therefore, no ethics approval was necessary.
Outbreak setting
The emergence of LRSE affected an interdisciplinary ICU of a 465 bed secondary care hospital in North Rhine-Westphalia. The 21 bed ICU included the following disciplines: internal medicine, surgery, urology, gynaecology and otorhinolaryngology. Patients were admitted from other hospitals, the community and from within the hospital.
Cases and bacterial isolates
Colonization was defined as detection of S. epidermidis without any sign of infection. We defined infections according to the current surveillance definitions for nosocomial infections of the CDC published by the National Reference Center for the Surveillance of Nosocomial Infections in 2011. 22 Linezolid resistance was defined as MIC .4 mg/L (according to EUCAST guidelines).
S. epidermidis was cultured according to routine diagnostic procedures. Screening for LRSE was performed using blood agar plates with linezolid discs to isolate staphylococci from the inhibition zone. Antibiotic susceptibility was determined using VITEK II. For environmental samples, swabs were cultured on blood agar plates and in tryptic soy broth. Identification of suspicious colonies was performed by MALDI-TOF. The S. epidermidis strains isolated were sent to the German National Reference Centre (NRC) for Staphylococci and Enterococci at the Robert Koch Institute (Wernigerode, Germany) for further characterization (n " 16; Table S1 , available as Supplementary data at JAC Online). The isolates were cultured on sheep blood agar and S. epidermidis species were confirmed by biochemical reactions and by the negative tube coagulase test using human plasma.
Antimicrobial susceptibility testing
At the NRC the antimicrobial susceptibility of the isolates was determined by broth microdilution applying EUCAST breakpoints (www.eucast.org); Etest V R for linezolid was used to confirm preliminary results. The following antibiotics were tested: penicillin, oxacillin, cefoxitin, fosfomycin, gentamicin, linezolid, erythromycin, clindamycin, tetracycline, tigecycline, vancomycin, teicoplanin, ciprofloxacin, mupirocin, moxifloxacin, daptomycin, fusidic acid, rifampicin and trimethoprim/sulfamethoxazole.
DNA extraction
Strains were grown overnight in tryptic soy broth at 37 C. DNA was extracted using the DNeasy tissue kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Lysostaphin (100 mg/L; Sigma, Munich, Germany) was added to the cell-lysis step.
Detection of the cfr gene and analysis of ribosomal target site mutations
Isolates were screened for the presence of the cfr gene by PCR as described previously. 23 To analyse possible linezolid resistance-mediating mutations, the rplC, rplD and rplV genes and partial sequences of the 23S rRNA were amplified by PCR. 5, 6 Amplicons were sequenced and the software package Geneious 7.1 was used to analyse the nucleotide and derived amino acid sequences. Results were compared with the S. epidermidis reference strain ATCC 12228.
Molecular typing
SmaI macrorestriction analysis was performed according to the HARMONY protocol. 24 Cluster analysis was performed with the BioNumerics software package (Applied Maths, Sint-Martens-Latem, Belgium), using the Dice coefficient, and visualized as a dendrogram by unweighted pair group method with arithmetic mean (UPGMA) with 1% tolerance and 1% optimization settings. A similarity cut-off of 90% was used to define clusters, which were designated by roman numbers. MLST for S. epidermidis was carried out as published elsewhere. 25 
WGS and bioinformatics analyses
WGS was performed on three cfr-carrying strains, representing the different clonal lineages: 13-04707 (ST168), 14-01514 (ST5) and 15-00164 (ST2). One nanogram of genomic DNA was used for library preparation utilizing the Nextera XT Library Prep Kit according to the manufacturer's instructions (Illumina). WGS was performed on a MiSeq instrument and in paired-end mode with a maximum readout of 2%300 bp. De novo assembly of the reads was carried out using the assembly algorithm a5-miseq and default parameters. 26 Obtained cfr-containing contigs produced overlapping sequences for isolate 14-01514 only, of which a preliminary plasmid sequence of 38.550 bp was extracted. Closed circle confirmation of all three putative plasmids was verified by PCR. Oligonucleotides 13-04707cc_fw and 13-04707cc_rv were used to amplify the contig ends of p13-04707 and p15-00164 or primers 14-01514cc_fw and 14-01514cc_rv to verify ring closure of p14-01514. A reaction consisting of 12.5 lL of 2 % DreamTaq Green Master Mix, 0.1 lM of each primer and 0.5 lL of whole genomic DNA in a total volume of 25 lL was subjected to the following PCR protocol: 94 C for 120 s, followed by 30 cycles of 94 C for 30 s, 55 C for 30 s and 72 C for 120 s with a final elongation for 240 s at 72 C. If necessary, Sanger sequencing of the PCR product was carried out. According to these results, isolate 14-01514 revealed an additional 693 bp compared with the consensus sequence extracted from WGS data, which were manually added to the final plasmid sequence (39.243 bp). Plasmid p14-01514 was annotated utilizing the automatic annotation tool provided by NCBI.
Amplification of the repetitive region of p13-04707 and p15-00164 was carried out using oligonucleotides 14-01514cc_fw and 14-01514cc_rv in a reaction volume and a PCR profile as stated above. Fragments were analysed by Sanger sequencing and evaluated in Geneious.
Accession numbers
Plasmid p14-01514 was deposited in GenBank under accession number KX520649. Raw reads of all three plasmids are available from SRA under accession number SRP078124.
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Recording of linezolid consumption
The monthly linezolid use in the ICU since 2013 was recorded in DDDs/ 100 patient-days with special emphasis on the usage between the end of 2013 and the beginning 2015. Linezolid doses of 600 mg/day were considered 1 DDD. Data were benchmarked to linezolid prescriptions of 2013-15. Additionally, the occurrence of patients with infections due to MRSA was investigated to explain the consumption of linezolid in 2014.
Results
Description of the outbreak, infection control measures and interventions
During November 2013 and January 2015 we detected LRSE in 14 patients ( Table 1 ). The median age of the patients was 76 (57-90) years with predominance of the male gender (10/4).
In July 2014 LRSE were identified in an intraoperative wound swab, a secretion drainage and in a blood culture of three patients ( Figure (Figure 1 ). To assess the spread of this outbreak the first infected patient (Patient 11) was screened for further colonization and tested positive in several screening cultures (axilla, rectal, wound swab). To evaluate the extent of colonization of other patients in this ward, axilla, rectum and wounds of the remaining patients were also screened. Two more patients (12 and 13) colonized with LRSE were detected. To evaluate contamination of the patient-near environment, an environmental screening of the room of Patient 11 was conducted, which revealed no LRSE. Nevertheless, all surfaces in the patient room were disinfected and all disposable medical products exchanged.
In order to prevent further transmission, we implemented contact isolation measures for all patients positive for LRSE. Contact isolation precautions included wearing gloves and aprons while entering the patient's room in compliance with the recommendations of the CDC and the Robert Koch Institute to manage patients with MRSA.
27,28 LRSE-positive patients were labelled in the hospital's alert system, including additional information about recommended isolation precautions. The ICU staff were trained again in hand hygiene and the management of medical devices and got timely feedback information about LRSE-positive patients.
In addition, linezolid consumption of the ICU was reviewed. The annual data corresponded to 7.0 DDDs/100 patient-days in 2013, 11.5 DDDs/100 patient-days in 2014 and 6.7 DDDs/100 patient-days in 2015. A significant increase in linezolid usage was observed, which started at the end of 2013 with a peak of 20.4 DDDs/100 patientdays in July 2014 (Figure 2 ). This peak correlated with the treatment of 10 patients with MRSA infections between February and July 2014, whereby linezolid was frequently part of the empirical choice of antibiotics, especially if MRSA pneumonia was suspected. After a maximum in monthly consumption in July 2014 linezolid use declined to a minimum of 2.02 DDDs/100 patient-days in October 2014. Again, in December 2014 linezolid use increased due to the treatment of MRSA patients. Both hospital and ICU consumption of linezolid and other antibiotic classes exceeded different reference levels, as indicated in Table S2 .
All except one patient (Patient 12) with LRSE had received linezolid, prior to colonization or infection with the resistant strain, as empirical treatment or for treatment of infections caused by MRSA or VRE (Table 2 ). To reduce linezolid use, prescriptions were discussed and the indications were double-checked by the infection control team and the physicians in charge. Alternative antibiotics were recommended to treat infections due to multiresistant Gram-positive organisms. A report was issued to the public health department.
Molecular typing of bacterial isolates
The entire set of 16 LRSE isolates was examined by macrorestriction analysis, which yielded three distinct clusters ( Table 2) : PFGE type I/ST168 (n " 5), PFGE type II/ST5 (n " 10) and PFGE type III/ST2 (n " 1).
Antimicrobial susceptibility and putative linezolidresistance mechanisms
The isolates showed decreased susceptibility to linezolid, exhibiting MICs in the range of 8 to .256 mg/L (Table 1) . They displayed a multiresistant phenotype, also being resistant to oxacillin (n " 15, 100%), gentamicin (n " 11, 73.3%), ciprofloxacin (n " 15, 100%), moxifloxacin (n " 15, 100%), co-trimoxazole (n " 14, 93.3%), mupirocin (n " 3, 20%), clindamycin (n " 9, 60%), erythromycin (n " 12, 80%), rifampicin (n " 10, 66.7%), tetracycline (n " 4, 26.67%) and teicoplanin (n " 2, 13.33%). Resistance to fusidic acid, tigecycline, vancomycin and daptomycin was not observed. Table 2 summarizes the results with respect to the presence of the cfr gene, mutations in the 23S rRNA and in genes encoding ribosomal proteins for all the isolates and also for the linezolidsusceptible control strain ATCC 12228. C2190T was the only modification found in the linezolid 23S rRNA binding site. Sequence chromatograms showed no evidence of nucleotide mixtures at the respective position. Amino acid alterations in L3 comprised Leu101Val, His146Gln, Gly152Asp, Val154Leu and Ala157Arg. Amino acid changes in L4 were found at the following positions: Ser81Arg; Asn158Ser; and a Gly71 insertion. Mutations in rplV were synonymous when detected. Ten strains (62.5%) harboured the cfr gene. In summary, all strains exhibiting PFGE type I/ST168 and PFGE type III/ST2 tested positive for cfr, whereas only four strains of the PFGE type II/ST5 cluster harboured the resistance determinant (Table 1) .
No apparent correlation was observed between the occurrence of certain nucleotide mutations, the presence of cfr and the level of linezolid resistance.
Description of cfr-carrying plasmids
Each cfr-positive isolate carried the cfr gene on an 40 kb plasmid as determined by S1 nuclease PFGE and Southern hybridization analysis using a cfr-specific probe (data not shown). De novo assembly and manual polishing of the contigs received by WGS produced a 39.243 bp plasmid for strain 14-01514 (termed p14-01514), which harboured cfr and the phenicol exporter fexA and had features highly similar to the previously published vector p12-02300. 15 Mapping of reads from S. epidermidis 14-01514 to
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p12-02300 revealed 99 SNPs. In addition, p12-2300 is 379 bp shorter compared with p14-01514. A BLAST search on this particular variable region yielded homologue sequences from plasmids of Staphylococcus aureus, S. epidermidis (p12-02300) and Staphylococcus cohnii, all of which were located in non-coding regions (not shown). Further examination of the sequence utilizing the Tandem Repeats Finder program 29 revealed a conserved repetitive region of 63 bp, which was present 8.7 times in p12-2300 and 14.7 times in p14-01514. The repetitive region was also investigated in S. epidermidis 13-04707 and 15-00164. PCR and subsequent Sanger sequencing showed that both cfr plasmids exhibit 189 bp less than p14-01514, which corresponds to three tandem repeats. This is in accordance with the results from Tandem Repeats Finder, indicating that the 63 bp repetitive sequence was present 11.7 times in p13-04707 and p15-00164, respectively.
With a final cfr-containing contig size of 38.273 and 38.450 bp after de novo assembly, no overlapping sequences representing putative plasmids were obtained for S. epidermidis isolates 13-04707 and 15-00164. A comparison of these contigs with p14-01514 yielded 100% identity of the truncated sequences from 13-04707 and 15-00164 to the novel vector, hence suggesting a highly similar plasmid content of these isolates. Taking into account that cfr plasmids from S. epidermidis 13-04707 and 15-00164 differ in the total amount of the 63 bp tandem repeats (see above) but are otherwise identical to p14-01514, the putative final plasmid sizes for p13-04707 and p15-00164 were set to 39.054 bp each. We herein identified three almost identical cfr plasmids with high similarity to the recently described vector from S. epidermidis 12-02300. 15 
Discussion
Management of the outbreak in the ICU
There is a plethora of articles describing the emergence and outbreaks with linezolid-resistant staphylococci worldwide. Outbreak of linezolid-resistant S. epidermidis in an ICU JAC However, there are just a few detailed reports including data on linezolid consumption, infection control measures and interventions. 10, 17, 19, 30, 31, 33 To control the outbreak we implemented contact isolation measures of LRSE-positive patients. Training courses on hand hygiene were organized for the ICU staff and data concerning the outbreak were regularly presented and discussed. A previous report from O'Connor et al. 17 showed that during a cfr-mediated LRSE outbreak the staff lacked knowledge concerning resistance mechanisms and ways of transmission. They implemented a hospital-wide education programme for healthcare staff thenceforward. 17 Another group from Spain reported an outbreak of linezolid-resistant S. aureus (LRSA) in 2008 and performed staff screening. While no staff member was found to be colonized, they could isolate LRSA from environmental surfaces. 33 We did not perform screening of staff for LRSE carriage and only conducted environmental screening of the room in the case of the bacteraemia patient, where no LRSE was detected. Overlapping stays of patients in the ICU with LRSE ST5 and ST168, respectively, suggested the dissemination of two endemic clones. This spread could have been caused by transmission directly via the hands of healthcare workers (HCWs), indirectly via environmental contamination or both. Whether or not the skin flora of HCWs serves as a source for LRSE is unclear and we did not investigate a potential impact. However, it is well known that HCWs serve as vectors for strain transmission from patient to patient via contaminated hands, skin and environments.
Empirical therapy of severe infections in MRSA-positive and MRSA-negative patients with linezolid seemed to facilitate the concomitant selection and spread of LRSE on the ward. Treatment with linezolid can suppress the susceptible cutaneous flora of patients. Hence, resistant strains may become predominant. Even if colonization of patients with LRSE is microbiologically not yet detectable, therapy with linezolid could initiate selection of the earlier-transmitted resistant strain.
Therefore, our infection control measures included the restriction of linezolid prescription, which has already been published by Mulanovich et al. 19 and others. [30] [31] [32] [33] [34] They proposed a threshold of 13 DDDs/100 patient-days being associated with the development of an outbreak of LRSE. 19 In accordance with the present study, the increased use of linezolid seemed efficient in promoting the emergence and persistence of linezolid-resistant clones in ICU patients. 20, 35 In conclusion, prospective surveillance, screening procedures, isolation precautions, education of ICU staff and providing them with information, control of MRSA and the restriction of linezolid use were efficient in controlling the emergence and transmission of LRSE.
Molecular epidemiology of LRSE
Worldwide, the nosocomial S. epidermidis population is dominated by strains that belong to the MLST clonal complex 5 (CC5). These epidemic clones are multiresistant, can persist in hospitals over a long period of time and seem to adapt quickly to different environments through recombination and frequent exchange of genetic mobile elements. [36] [37] [38] [39] In the present study three different STs were identified: ST2, ST5 and ST168 (a single-locus variant of ST2), all of them belonging to CC5. SmaI macrorestriction analysis confirmed the presence of three distinct clusters; no further differentiation was possible. Ribosomal mutations were analysed, thereby confirming an identical pattern of ribosomal protein alterations within the respective clade and indicating the spread of LRSE ST5 and ST168 on the ward. LRSE ST2 was only detected once, in January 2015, from the blood culture of the last defined case. LRSE ST168 and ST2 and 4/10 LRSE ST5 carried a cfr plasmid. Due to the sequencing of one plasmid from each clonal lineage, we confirmed Weßels et al.
the presence of a highly similar cfr plasmid in all three genetic backgrounds. The acquisition of this plasmid via horizontal gene transfer is possible, as similar scenarios with the respective conjugative cfr vectors are described elsewhere. 15, 40 There are only a few reports dealing with outbreaks caused by LRSE in Europe. 34 In 2015 we published data concerning clusters of LRSE ST2 and ST22 in German hospitals, where we showed evidence for the acquisition of cfr plasmids via horizontal gene transfer during spread of the respective strains. 15 The same year, O'Connor et al.
17
described the first cfr-mediated LRSE outbreak in the Republic of Ireland. Several European studies present evidence for the presence of endemic LRSE clones that circulate in hospital settings. 18, 41, 42 Similar to our study, these strains differ from commensal S. epidermidis isolates by exhibiting MDR and biofilmforming capabilities, therefore being probably more successful in the hospital environment. 39, 43, 44 Linezolid-resistance mechanisms
We examined the isolates for molecular mechanisms that may contribute to linezolid resistance in CoNS. All strains showed a C2190T modification of the 23S rRNA that is occasionally described in linezolid-resistant CoNS. 34 In contrast to G2576T, its association with increased linezolid MICs has not been functionally verified so far. 1, 7, 34 Mutations in rplC and rplD genes, encoding 50S ribosomal proteins of the PTC of the ribosome, revealed non-synonymous mutations in the 50S ribosomal proteins L3 and L4. The impact of these alterations on the structure of the PTC and linezolid binding remains to be determined, as the influence of L3 mutations on its tertiary folding was shown in silico. 45 An earlier study using laboratory-derived linezolid-resistant strains confirmed a correlation for selected L3 and L4 mutations. 46 Although many articles report multiple ribosomal mutations in clinical LRSE, data concerning the functional proof of the putative resistance mechanisms are rare. 1, 8, 15, 47 However, a combination of mutations leads to functional and structural adaptation to linezolid and promotes a faster growth rate of linezolid-dependent strains. 20, 35 Ten (62.5%) of our isolates additionally carried a cfr-positive plasmid. In all cases cfr was detected in combination with alterations in ribosomal genes. WGS showed that all cfr plasmids were highly similar to the recently described cfr plasmid p12-02300 from a clinical S. epidermidis isolate in Germany 15 and differed only by varying numbers of tandem repeats. The function of these sequences requires further investigation. As a result of highly similar plasmid content, the spread of endemic clones in addition to dissemination of the cfr plasmid(s) within the hospital environment can be suspected.
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